^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD0305

    i
    Other names: AZD0305, LM-305, AZD 0305, LM 305, AZD-0305, LM305
    Company:
    AstraZeneca, Sino Biopharm
    Drug class:
    Microtubule inhibitor, GPRC5D-targeted antibody-drug conjugate
    Related drugs:
    6ms
    AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=226, Recruiting, AstraZeneca | N=108 --> 226 | Trial completion date: Aug 2026 --> Mar 2027 | Trial primary completion date: Aug 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    AZD0305
    9ms
    AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=99, Recruiting, AstraZeneca | Trial completion date: Nov 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    AZD0305
    almost2years
    AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=84, Recruiting, AstraZeneca | N=64 --> 84
    Enrollment change • Combination therapy
    |
    AZD0305
    almost2years
    A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=64, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD0305
    2years
    Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, LaNova Medicines Limited | N=380 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    AZD0305 • dexamethasone injection
    2years
    A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=64, Not yet recruiting, AstraZeneca
    New P1/2 trial
    |
    AZD0305